A new milestone in bacterial vaccine research: after several years of intensive research, validation work, and cross-institutional collaboration, the study on the development and qualification of a Multiplex assay for Shigella has now been officially published on Vaccine (ScienceDirect).
This achievement responds to an urgent global need: the lack of standardized, high-performance analytical tools to evaluate new bacterial vaccines, particularly against Shigella, a priority pathogen responsible for severe diarrheal disease in young children and vulnerable populations.
Why this matters
Shigella remains a global health priority identified by the World Health Organization. Progress in vaccine development depends on reliable laboratory methodologies capable of measuring functional immune response quickly and accurately.
The newly validated Multiplex assay provides:
- multi-antigen analysis in a single test
- improved reproducibility and precision
- faster data generation for clinical evaluation
- a platform adaptable to future bacterial vaccine studies
A global scientific collaboration
The work is the result of a multi-partner effort involving:
- Gates Medical Research Institute
- Hogrefe Consulting, Inc.
- VisMederi Srl
- GSK Vaccines Institute for Global Health (GVGH)
- Luminex Corporation
- World Health Organization (WHO)
- LimmaTech Biologics AG
- University of Siena
This assay represents a key tool for future clinical trials on Shigella vaccines and may serve as a reference approach for other enteric bacterial pathogens.
🔗 Read the publication:
https://www.sciencedirect.com/science/article/abs/pii/S0264410X25011934
